Cargando…

Haemochromatosis in end-stage renal disease: when waste is a treatment option

For patients with end-stage renal disease and hereditary haemochromatosis, prevention and treatment of anaemia differ from usual nephrologic guidelines. Monitoring of individual disease progression and ferritin levels is crucial. We describe a case of a young haemodialysis patient with early-stage o...

Descripción completa

Detalles Bibliográficos
Autores principales: Oettl, Tobias, Dickenmann, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4421493/
https://www.ncbi.nlm.nih.gov/pubmed/25949284
http://dx.doi.org/10.1093/ndtplus/sfn161
_version_ 1782369881894682624
author Oettl, Tobias
Dickenmann, Michael
author_facet Oettl, Tobias
Dickenmann, Michael
author_sort Oettl, Tobias
collection PubMed
description For patients with end-stage renal disease and hereditary haemochromatosis, prevention and treatment of anaemia differ from usual nephrologic guidelines. Monitoring of individual disease progression and ferritin levels is crucial. We describe a case of a young haemodialysis patient with early-stage organ dysfunction caused by hereditary haemochromatosis, in whom iron stores have successfully been depleted with phlebotomy and supplemental erythropoietin over 22 months. Target ferritin levels could finally be reached without severe, persisting or symptomatic anaemia.
format Online
Article
Text
id pubmed-4421493
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-44214932015-05-06 Haemochromatosis in end-stage renal disease: when waste is a treatment option Oettl, Tobias Dickenmann, Michael NDT Plus Case Report For patients with end-stage renal disease and hereditary haemochromatosis, prevention and treatment of anaemia differ from usual nephrologic guidelines. Monitoring of individual disease progression and ferritin levels is crucial. We describe a case of a young haemodialysis patient with early-stage organ dysfunction caused by hereditary haemochromatosis, in whom iron stores have successfully been depleted with phlebotomy and supplemental erythropoietin over 22 months. Target ferritin levels could finally be reached without severe, persisting or symptomatic anaemia. Oxford University Press 2009-02 2008-10-21 /pmc/articles/PMC4421493/ /pubmed/25949284 http://dx.doi.org/10.1093/ndtplus/sfn161 Text en © The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Case Report
Oettl, Tobias
Dickenmann, Michael
Haemochromatosis in end-stage renal disease: when waste is a treatment option
title Haemochromatosis in end-stage renal disease: when waste is a treatment option
title_full Haemochromatosis in end-stage renal disease: when waste is a treatment option
title_fullStr Haemochromatosis in end-stage renal disease: when waste is a treatment option
title_full_unstemmed Haemochromatosis in end-stage renal disease: when waste is a treatment option
title_short Haemochromatosis in end-stage renal disease: when waste is a treatment option
title_sort haemochromatosis in end-stage renal disease: when waste is a treatment option
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4421493/
https://www.ncbi.nlm.nih.gov/pubmed/25949284
http://dx.doi.org/10.1093/ndtplus/sfn161
work_keys_str_mv AT oettltobias haemochromatosisinendstagerenaldiseasewhenwasteisatreatmentoption
AT dickenmannmichael haemochromatosisinendstagerenaldiseasewhenwasteisatreatmentoption